#obesity drug market

Total 1 articles

Novo Nordisk's Obesity Drug Stumble: What It Means for Your Wallet

Novo Nordisk's CagriSema disappoints in trials against Eli Lilly's obesity treatments. Analysis of the trillion-dollar market battle and implications for patients and investors.

Feb 23, 2026